Bolt’s setback didn’t come out of the blue
The company scraps its lead project and clears out its C-suite, but there was already a precedent.
A flurry of first-in-human trial initiations
Projects from Affini-T, Bolt, Chimeric and Alentis, all hitting novel targets, as well as one from A2 using an old one, are set for first clinical trial entry.
